Anti usf1

Nuclear extracts and whole cell extracts were prepared using NUM buffer as described in Reinke et al.^{18 (link)} or Nuclear/Cytosol Fractionation Kit (BioVision). Immunoblotting was carried out as described previously^{31 (link)}. The antibodies used were anti-Sp1 (07-645, Millipore), anti-Actin (sc-8432) and anti-USF1 (sc-229, Santa Cruz Biotechnology), anti-HSF1 (#4356, Cell Signal Technology), and anti-HSP70 (SPA-812) and anti-HSC70/HSP70 (SPA-822, StressGen).

The antibodies we used are as follows: anti-E-cadherin (Abcam # ab40772), anti-Vimentin (Abcam # ab92547), anti-Fibronectin (Proteintech # 15613–1-AP), anti-AGO2 (Abcam # ab57113), anti-USF1 (Santa Cruz # sc-390,027), anti-RNA polymerase II (Santa Cruz # sc-47,701), anti-TGF-β1 (Abcam # ab92486), anti-ESRP1 (Abcam # ab107278), anti-p-Smad2 (Cell Signaling Technology # 8828), anti-p-Smad3 (Cell Signaling Technology # 9520), anti-Smad2/3 (Cell Signaling Technology # 8685), anti-GAPDH (Proteintech # 10494–1-AP) and anti-β-actin (Cell Signaling Technology # 4970). Actinomycin D and RNase R were purchased from Sigma-Aldrich (St Louis, MO, USA) and Epicentre Technologies (Madison, WI, USA), respectively. The TGF-β receptor type I/II inhibitor LY2109761 was obtained from Selleckchem Chemicals (Houston, TX, USA).